GlassScriptPhysician profile
April M Brooks
NPI 1023251386
$2,071.01
in general payments reported to CMS, 2019-2025
28 companies · $335 in 2025
The $335 reported for 2025 was more than what 77% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $491 · 2023: $451 · 2024: $199 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $448.43 | 2021-2024 | Wegovy |
| Abbvie INC. | $278.79 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $173.70 | 2021-2025 | |
| Hologic Sales and Service, LLC | $157.12 | 2022-2025 | Novasure, Myosure Tissue Removal Device, Coolseal Generator |
| Bausch Health US, LLC | $107.24 | 2021-2022 | |
| Sage Therapeutics, LLC | $98.23 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $73.85 | 2023-2025 | |
| Shield Therapeutics INC | $67.95 | 2023-2024 | Accrufer |
| Scynexis, INC. | $65.60 | 2021-2022 | |
| Astellas Pharma US INC | $63.88 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $59.14 | 2021-2025 | Slynd |
| Aspira Women'S Health INC | $53.90 | 2021 | |
| Lilly USA, LLC | $42.01 | 2022-2023 | Emgality, Zepbound |
| Urovant Sciences INC | $41.86 | 2022 | |
| Sumitomo Pharma America, INC. | $41.43 | 2024-2025 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38.98 | 2021 | |
| Pfizer INC. | $35.24 | 2023 | |
| Organon LLC | $34.58 | 2025 | Nexplanon |
| Evofem Biosciences, INC. | $30.26 | 2021 | |
| Roche Diagnostics Corporation | $21.29 | 2021 | |
| Virtus Pharmaceuticals LLC | $20.46 | 2021 | |
| Daiichi Sankyo INC. | $19.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.25 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.66 | 2025 | Qelbree |
| Solventum Corporation | $17.06 | 2025 | Prevena |
| Smith+Nephew, INC. | $15.31 | 2022 | |
| Agile Therapeutics, INC. | $14.77 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.